Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P35462
UPID:
DRD3_HUMAN
Alternative names:
Dopamine D3 receptor
Alternative UPACC:
P35462; A1A4V5; Q4VBM8
Background:
The D(3) dopamine receptor, also known as the Dopamine D3 receptor, plays a crucial role in the central nervous system. Its activity is mediated by G proteins which inhibit adenylyl cyclase, promoting cell proliferation. This receptor is pivotal in modulating neurotransmission and brain function.
Therapeutic significance:
The D(3) dopamine receptor is implicated in hereditary essential tremor and schizophrenia. Variants affecting this gene can lead to susceptibility to these conditions, highlighting its potential as a target for therapeutic strategies aimed at treating movement disorders and psychotic disorders.